Az epipharynxrák lokális kiújulásának ismételt sugárkezelése.

Translated title of the contribution: Repeated radiotherapy in locally recurrent nasopharyngeal cancer

Erzsébet Lengyel, Károly Baricza, A. Somogyi, Judit Olajos, Zsuzsanna Pápai, Mária Gödény, György Németh, O. Ésik

Research output: Contribution to journalArticle

Abstract

PATIENTS AND METHODS: In the period between 1993 and 2000, 20 patients with nasopharyngael cancer were re-irradiated for locally recurrent carcinomas. The median duration between primary treatment and recurrence was 30 months. Brachytherapy was the method most frequently used in 10 cases alone, and in 8 cases in combination with external beam therapy. 2 patients underwent only external beam therapy. The external irradiation was performed with CT/MRI-based treatment planning. Brachytherapy involved a high dose rate afterloading method. The cumulative dose of re-irradiation was 20-60 Gy. RESULTS: After a median follow-up of 37 months the overall survival and the local control were 60% (12/20) and 58% (7/12), respectively. 7 of the 12 surviving patients are currently tumour-free. After primary irradiation xerostomy occurred in all patients as an unavoidable side-effect of the treatment. A severe (grade 3 or higher according to the Common Toxicity Criteria version 2.0) late-side effect has so far been observed in 2 cases (10%). Authors' results lie in the medial range of the data in the international literature, though the rate of radiogen side-effects in the patient group is low. Both results are assumed to be a consequence of the re-irradiation dose being lower than the value considered optimum in the recent literature. CONCLUSIONS: Re-irradiation of locally recurrent nasopharyngeal cancers is an efficient treatment modality, which should be used as a combination of external beam therapy and brachytherapy. The optimum cumulative dose is about 50-60 Gy. This dose results in a 5 years survival rate of about 40% with an acceptable (30%) risk. The results of re-irradiation may be improved, if PET is used to determine the extent of the surviving tumour tissue. This can help in the choice of the proper treatment modality.

Original languageHungarian
Pages (from-to)2343-2350
Number of pages8
JournalOrvosi Hetilap
Volume143
Issue number41
Publication statusPublished - Oct 13 2002

Fingerprint

Nasopharyngeal Neoplasms
Radiotherapy
Brachytherapy
Therapeutics
Neoplasms
Survival Rate
Carcinoma
Recurrence
Survival
Re-Irradiation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Lengyel, E., Baricza, K., Somogyi, A., Olajos, J., Pápai, Z., Gödény, M., ... Ésik, O. (2002). Az epipharynxrák lokális kiújulásának ismételt sugárkezelése. Orvosi Hetilap, 143(41), 2343-2350.

Az epipharynxrák lokális kiújulásának ismételt sugárkezelése. / Lengyel, Erzsébet; Baricza, Károly; Somogyi, A.; Olajos, Judit; Pápai, Zsuzsanna; Gödény, Mária; Németh, György; Ésik, O.

In: Orvosi Hetilap, Vol. 143, No. 41, 13.10.2002, p. 2343-2350.

Research output: Contribution to journalArticle

Lengyel, E, Baricza, K, Somogyi, A, Olajos, J, Pápai, Z, Gödény, M, Németh, G & Ésik, O 2002, 'Az epipharynxrák lokális kiújulásának ismételt sugárkezelése.', Orvosi Hetilap, vol. 143, no. 41, pp. 2343-2350.
Lengyel E, Baricza K, Somogyi A, Olajos J, Pápai Z, Gödény M et al. Az epipharynxrák lokális kiújulásának ismételt sugárkezelése. Orvosi Hetilap. 2002 Oct 13;143(41):2343-2350.
Lengyel, Erzsébet ; Baricza, Károly ; Somogyi, A. ; Olajos, Judit ; Pápai, Zsuzsanna ; Gödény, Mária ; Németh, György ; Ésik, O. / Az epipharynxrák lokális kiújulásának ismételt sugárkezelése. In: Orvosi Hetilap. 2002 ; Vol. 143, No. 41. pp. 2343-2350.
@article{4727c41d64554025b5bebd7d6e95ff28,
title = "Az epipharynxr{\'a}k lok{\'a}lis ki{\'u}jul{\'a}s{\'a}nak ism{\'e}telt sug{\'a}rkezel{\'e}se.",
abstract = "PATIENTS AND METHODS: In the period between 1993 and 2000, 20 patients with nasopharyngael cancer were re-irradiated for locally recurrent carcinomas. The median duration between primary treatment and recurrence was 30 months. Brachytherapy was the method most frequently used in 10 cases alone, and in 8 cases in combination with external beam therapy. 2 patients underwent only external beam therapy. The external irradiation was performed with CT/MRI-based treatment planning. Brachytherapy involved a high dose rate afterloading method. The cumulative dose of re-irradiation was 20-60 Gy. RESULTS: After a median follow-up of 37 months the overall survival and the local control were 60{\%} (12/20) and 58{\%} (7/12), respectively. 7 of the 12 surviving patients are currently tumour-free. After primary irradiation xerostomy occurred in all patients as an unavoidable side-effect of the treatment. A severe (grade 3 or higher according to the Common Toxicity Criteria version 2.0) late-side effect has so far been observed in 2 cases (10{\%}). Authors' results lie in the medial range of the data in the international literature, though the rate of radiogen side-effects in the patient group is low. Both results are assumed to be a consequence of the re-irradiation dose being lower than the value considered optimum in the recent literature. CONCLUSIONS: Re-irradiation of locally recurrent nasopharyngeal cancers is an efficient treatment modality, which should be used as a combination of external beam therapy and brachytherapy. The optimum cumulative dose is about 50-60 Gy. This dose results in a 5 years survival rate of about 40{\%} with an acceptable (30{\%}) risk. The results of re-irradiation may be improved, if PET is used to determine the extent of the surviving tumour tissue. This can help in the choice of the proper treatment modality.",
author = "Erzs{\'e}bet Lengyel and K{\'a}roly Baricza and A. Somogyi and Judit Olajos and Zsuzsanna P{\'a}pai and M{\'a}ria G{\"o}d{\'e}ny and Gy{\"o}rgy N{\'e}meth and O. {\'E}sik",
year = "2002",
month = "10",
day = "13",
language = "Hungarian",
volume = "143",
pages = "2343--2350",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "41",

}

TY - JOUR

T1 - Az epipharynxrák lokális kiújulásának ismételt sugárkezelése.

AU - Lengyel, Erzsébet

AU - Baricza, Károly

AU - Somogyi, A.

AU - Olajos, Judit

AU - Pápai, Zsuzsanna

AU - Gödény, Mária

AU - Németh, György

AU - Ésik, O.

PY - 2002/10/13

Y1 - 2002/10/13

N2 - PATIENTS AND METHODS: In the period between 1993 and 2000, 20 patients with nasopharyngael cancer were re-irradiated for locally recurrent carcinomas. The median duration between primary treatment and recurrence was 30 months. Brachytherapy was the method most frequently used in 10 cases alone, and in 8 cases in combination with external beam therapy. 2 patients underwent only external beam therapy. The external irradiation was performed with CT/MRI-based treatment planning. Brachytherapy involved a high dose rate afterloading method. The cumulative dose of re-irradiation was 20-60 Gy. RESULTS: After a median follow-up of 37 months the overall survival and the local control were 60% (12/20) and 58% (7/12), respectively. 7 of the 12 surviving patients are currently tumour-free. After primary irradiation xerostomy occurred in all patients as an unavoidable side-effect of the treatment. A severe (grade 3 or higher according to the Common Toxicity Criteria version 2.0) late-side effect has so far been observed in 2 cases (10%). Authors' results lie in the medial range of the data in the international literature, though the rate of radiogen side-effects in the patient group is low. Both results are assumed to be a consequence of the re-irradiation dose being lower than the value considered optimum in the recent literature. CONCLUSIONS: Re-irradiation of locally recurrent nasopharyngeal cancers is an efficient treatment modality, which should be used as a combination of external beam therapy and brachytherapy. The optimum cumulative dose is about 50-60 Gy. This dose results in a 5 years survival rate of about 40% with an acceptable (30%) risk. The results of re-irradiation may be improved, if PET is used to determine the extent of the surviving tumour tissue. This can help in the choice of the proper treatment modality.

AB - PATIENTS AND METHODS: In the period between 1993 and 2000, 20 patients with nasopharyngael cancer were re-irradiated for locally recurrent carcinomas. The median duration between primary treatment and recurrence was 30 months. Brachytherapy was the method most frequently used in 10 cases alone, and in 8 cases in combination with external beam therapy. 2 patients underwent only external beam therapy. The external irradiation was performed with CT/MRI-based treatment planning. Brachytherapy involved a high dose rate afterloading method. The cumulative dose of re-irradiation was 20-60 Gy. RESULTS: After a median follow-up of 37 months the overall survival and the local control were 60% (12/20) and 58% (7/12), respectively. 7 of the 12 surviving patients are currently tumour-free. After primary irradiation xerostomy occurred in all patients as an unavoidable side-effect of the treatment. A severe (grade 3 or higher according to the Common Toxicity Criteria version 2.0) late-side effect has so far been observed in 2 cases (10%). Authors' results lie in the medial range of the data in the international literature, though the rate of radiogen side-effects in the patient group is low. Both results are assumed to be a consequence of the re-irradiation dose being lower than the value considered optimum in the recent literature. CONCLUSIONS: Re-irradiation of locally recurrent nasopharyngeal cancers is an efficient treatment modality, which should be used as a combination of external beam therapy and brachytherapy. The optimum cumulative dose is about 50-60 Gy. This dose results in a 5 years survival rate of about 40% with an acceptable (30%) risk. The results of re-irradiation may be improved, if PET is used to determine the extent of the surviving tumour tissue. This can help in the choice of the proper treatment modality.

UR - http://www.scopus.com/inward/record.url?scp=17144432506&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17144432506&partnerID=8YFLogxK

M3 - Article

C2 - 12434736

AN - SCOPUS:17144432506

VL - 143

SP - 2343

EP - 2350

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 41

ER -